Metabolic Syndrome - Short Notes

Definition

• Basic Medical Biochemistry - A Clinical Approach, 6e

Diagnostic Criteria (NCEP ATP III - most widely used)

The IDF (International Diabetes Federation) uses central obesity as a mandatory criterion plus any 2 of the remaining 4.

• Basic Medical Biochemistry - A Clinical Approach, 6e, p. 1166

Pathophysiology

1. Visceral adiposity and free fatty acids (FFA/NEFA)
   • Enlarged adipocytes release excess non-esterified fatty acids (NEFA) into circulation
   • Muscle switches to FFA oxidation → acetyl-CoA accumulates → citrate exported → PFK-1 inhibited → glucose uptake by muscle falls
   • This manifests as peripheral insulin resistance
2. Pancreatic β-cell dysfunction
   • Elevated NEFA also impair glucose-stimulated insulin secretion from β-cells
   • Normal secretion depends on glucose metabolism generating ATP (closes K+ channels) → membrane depolarization → Ca2+ influx → insulin exocytosis
   • NEFA-induced lipotoxicity disrupts this pathway
3. Adipokine dysregulation
   • Decreased adiponectin (insulin-sensitizing)
   • Increased leptin resistance, TNF-α, IL-6 (pro-inflammatory)
   • Chronic low-grade inflammation drives endothelial dysfunction
4. Dyslipidemia
   • Excess NEFA → hepatic VLDL overproduction → hypertriglyceridemia
   • Hypertriglyceridemia → CETP-mediated HDL depletion → low HDL
5. Hypertension mechanism
   • Hyperinsulinemia → Na+ retention → increased sympathetic tone
   • Endothelial dysfunction reduces nitric oxide-mediated vasodilation

• Basic Medical Biochemistry - A Clinical Approach, 6e

Risk Factors / Associations

• Central obesity (primary driver)
• Physical inactivity
• High-carbohydrate / high-fat diet
• Genetic predisposition
• Polycystic ovary syndrome (PCOS) - metabolic syndrome is a major comorbidity in women with PCOS
• Antipsychotic medications - especially clozapine and olanzapine (highest risk); quetiapine, risperidone carry moderate risk; first-generation antipsychotics carry lowest risk
• Aging, menopause
• Goldman-Cecil Medicine International Edition; Berek & Novak's Gynecology

Clinical Consequences

• Type 2 diabetes mellitus - 5x increased risk
• Cardiovascular disease - coronary artery disease, stroke, heart failure
• Non-alcoholic fatty liver disease (NAFLD)/NASH
• Chronic kidney disease
• Sleep apnea
• Hyperuricemia / gout
• Polycystic ovary syndrome

Management

1. Lifestyle Modification (first-line)

• Weight loss of ≥5-10% body weight improves all components
• Dietary changes: caloric deficit of 500-1000 kcal/day; <30% fat, <10% saturated fat; increased fiber and whole grains
• Exercise: structured aerobic exercise ≥30 min/day, most days of the week
• Behavioral therapy and stress reduction

2. Pharmacotherapy (for individual components)

• Insulin resistance/hyperglycemia: Metformin (first-line); GLP-1 receptor agonists (e.g., liraglutide) - also promote weight loss and reduce waist circumference
• Dyslipidemia: Statins for LDL/cardiovascular risk; fibrates or niacin for hypertriglyceridemia; raising HDL
• Hypertension: ACE inhibitors or ARBs preferred (also improve insulin sensitivity); avoid beta-blockers as monotherapy
• Obesity pharmacotherapy: Orlistat; newer agents (GLP-1 agonists, GIP/GLP-1 dual agonists)

3. Bariatric Surgery

• Considered when BMI >40 kg/m² or >35 kg/m² with high-risk obesity-related conditions after failure of other treatments
• Can produce remission of all syndrome components
• Berek & Novak's Gynecology; Goldman-Cecil Medicine

Special Populations

• Psychiatric patients on antipsychotics: Monitor weight and BMI every visit (especially first 6 months), blood pressure and fasting glucose every 3 months. Metformin 850 mg BID can significantly reduce antipsychotic-associated weight gain and metabolic abnormalities. Liraglutide is effective for patients on clozapine/olanzapine.
• Women with PCOS: Metabolic syndrome highly prevalent; weight loss of >5-15% reduces free testosterone, improves menstrual function, ovulation, and metabolic parameters.

Key Points to Remember

• Abdominal obesity is the hallmark and most common presenting feature
• Insulin resistance links all components - treat it to treat the syndrome
• The syndrome doubles cardiovascular mortality risk
• Treatment of the syndrome as a whole (rather than each risk factor in isolation) is debated, but component-based treatment reduces overall risk
• GLP-1 receptor agonists (semaglutide, liraglutide) have emerged as among the most effective pharmacological tools for addressing multiple components simultaneously

Recent Evidence Note (2024): A systematic review (PMID 39166637) confirmed aerobic exercise significantly improves multiple metabolic syndrome components in older adults with T2DM. Diet quality scores show strong inverse associations with metabolic syndrome prevalence in children and adolescents (PMID 39331350).